You need to be logged in to see the full monograph.


Date of issue: May 2020, Version: 2

bumps logo
A corresponding patient information leaflet on USE OF METHYLDOPA IN PREGNANCY is available.

Methyldopa is an antihypertensive agent thought to act by stimulating α2-adrenergic receptors.

The National Institute for Health and Care Excellence (NICE) recommends that labetalol is offered as first-line antihypertensive treatment during pregnancy, with alternatives being nifedipine if labetolol is not suitable, and methyldopa if both labetalol and nifedipine are not suitable. If a woman prescribed methyldopa during pregnancy requires ongoing postpartum treatment, NICE recommends that methyldopa is discontinued within two days of delivery and an alternative antihypertensive treatment initiated. This is due to an increased risk of depression with methyldopa use.

The limited available data do not demonstrate increased overall risks of congenital malformation or miscarriage following use of methyldopa in the first trimester but are inadequate to rule this out. While specific associations between first trimester methyldopa use and Ebstein’s anomaly, and digestive, genital and urinary tract defects have been reported in single studies, further analyses are needed to confirm or refute these associations. The limited available data do not currently raise concerns of increased risks of preterm delivery, small for gestational age, perinatal death, neonatal complications or adverse neurodevelopmental outcomes directly related to methyldopa exposure.

Exposure to methyldopa at any stage in pregnancy is not itself an indication for additional fetal monitoring, although pregnant women with hypertension will be offered consultant-led care and additional monitoring of blood pressure, proteinuria, and ultrasound assessment of fetal growth and wellbeing. Other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from to ensure you are using the most up-to-date version.